Peptide Library / Detail
Liraglutide
Half-life
13 hours
Delivery
Subcutaneous injection
Dosage
—
Research Use Only
All products listed are for laboratory research only — not for human consumption. By browsing, you acknowledge these terms.
Purchase
Description
Liraglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1) with 97% sequence homology to native GLP-1. Originally developed for type 2 diabetes management, it has been approved for chronic weight management due to its effects on appetite regulation and glucose metabolism. The peptide has been modified with a fatty acid side chain to increase its half-life and duration of action.
Usage
For weight management, typical dosing starts at 0.6 mg subcutaneously once daily, with weekly increments of 0.6 mg until reaching the maintenance dose of 3.0 mg daily. For diabetes management, doses typically range from 0.6 mg to 1.8 mg daily. Administered at any time of day, with or without meals, though consistency in timing is recommended. Dose escalation helps minimize gastrointestinal side effects.
Mechanism of Action
Liraglutide activates GLP-1 receptors in pancreatic beta cells, enhancing glucose-dependent insulin secretion and suppressing inappropriately elevated glucagon secretion. It slows gastric emptying and acts on appetite centers in the hypothalamus to reduce food intake and increase satiety. The fatty acid modification allows binding to albumin, protecting it from degradation and extending its pharmacological activity.
Benefits(6)
- Significant weight loss (5-10% of body weight on average)
- Improved glycemic control and reduced HbA1c in diabetic patients
- Reduced appetite and increased feelings of fullness
- Cardiovascular risk reduction in patients with type 2 diabetes
- Lower blood pressure in many patients
- Potential reduction in fatty liver disease markers
Side Effects(8)
- Nausea (most common, especially during dose escalation)
- Vomiting and diarrhea
- Constipation
- Headache
- Potential increased heart rate
- Risk of pancreatitis (rare but serious)
- Gallbladder problems including gallstones
- Injection site reactions